These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20123566)

  • 1. Transdermal delivery of dopamine receptor agonists.
    Reichmann H
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S93-6. PubMed ID: 20123566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U; Del Dotto P; Rascol O
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of dopamine agonists in Parkinson's disease: an update.
    Bonuccelli U; Pavese N
    Expert Rev Neurother; 2007 Oct; 7(10):1391-9. PubMed ID: 17939774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies.
    Onofrj M; Bonanni L; De Angelis MV; Anzellotti F; Ciccocioppo F; Thomas A
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S85-92. PubMed ID: 20123565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE; Pahwa R
    Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P
    Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature.
    Thobois S
    Clin Ther; 2006 Jan; 28(1):1-12. PubMed ID: 16490575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal Delivery of Pramipexole Using Microneedle Technology for the Potential Treatment of Parkinson's Disease.
    McGuckin MB; Hutton ARJ; Davis ER; Sabri AHB; Ripolin A; Himawan A; Naser YA; Ghanma R; Greer B; McCarthy HO; Paredes AJ; Larrañeta E; Donnelly RF
    Mol Pharm; 2024 May; 21(5):2512-2533. PubMed ID: 38602861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine receptor agonists and sleep disturbances in Parkinson's disease.
    Chaudhuri KR; Logishetty K
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S101-4. PubMed ID: 20123546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
    Stockwell KA; Virley DJ; Perren M; Iravani MM; Jackson MJ; Rose S; Jenner P
    Exp Neurol; 2008 May; 211(1):172-9. PubMed ID: 18321484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease.
    Joyce JN; Millan MJ
    Curr Opin Pharmacol; 2007 Feb; 7(1):100-5. PubMed ID: 17174156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease.
    Wolters ECh
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S18-23. PubMed ID: 17702631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic evaluation of pramipexole.
    Antonini A; Calandrella D
    Expert Opin Drug Metab Toxicol; 2011 Oct; 7(10):1307-14. PubMed ID: 21892895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Saudi Med J; 2002 Oct; 23(10):1165-75. PubMed ID: 12436117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease.
    Reichmann H; Bilsing A; Ehret R; Greulich W; Schulz JB; Schwartz A; Rascol O
    J Neurol; 2006 Aug; 253 Suppl 4():IV36-8. PubMed ID: 16944356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.